| scholarly article | Q13442814 |
| P2093 | author name string | Dimos D. Mitsikostas | |
| P2860 | cites work | Prevalence of headache in Europe: a review for the Eurolight project | Q24595087 |
| Medical world | Q27720441 | ||
| When words are painful: unraveling the mechanisms of the nocebo effect | Q31106595 | ||
| Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer | Q33625012 | ||
| Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging | Q33750230 | ||
| Nocebo-induced hyperalgesia during local anesthetic injection. | Q34020725 | ||
| OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program | Q34116531 | ||
| Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches | Q34158126 | ||
| Nonspecific medication side effects and the nocebo phenomenon | Q34519096 | ||
| The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. | Q34581978 | ||
| Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses | Q34746177 | ||
| Magnitude, impact, and stability of primary headache subtypes: 30 year prospective Swiss cohort study | Q35181106 | ||
| The nocebo effect and its relevance for clinical practice | Q35196454 | ||
| Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls | Q36013751 | ||
| A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect | Q37113699 | ||
| New insights into the placebo and nocebo responses | Q37230629 | ||
| The potential of a placebo/nocebo effect in pharmacogenetics | Q37335304 | ||
| A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
| The nocebo effect: a reason for patients' non-adherence to generic substitution? | Q37775939 | ||
| Epidemiological classification and social impact of chronic headache | Q37791924 | ||
| Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials? | Q37813732 | ||
| The placebo response: how words and rituals change the patient's brain | Q37881388 | ||
| Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice | Q37942656 | ||
| The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients | Q39390370 | ||
| The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin | Q41499548 | ||
| Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans | Q42858321 | ||
| Diagnosis of lactose intolerance and the "nocebo" effect: the role of negative expectations | Q43130401 | ||
| A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. | Q43662938 | ||
| Chronic Migraine, Classification, Differential Diagnosis, and Epidemiology | Q44199010 | ||
| Placebo adverse events in headache trials: headache as an adverse event of placebo | Q44570003 | ||
| Nocebo effects in multiple sclerosis trials: a meta-analysis | Q46822234 | ||
| Nonspecific side effects of oral contraceptives: nocebo or noise? | Q50654952 | ||
| The role of learning in nocebo and placebo effects | Q51960960 | ||
| Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide | Q73485107 | ||
| The nocebo reaction | Q79032458 | ||
| Induction of nocebo and placebo effects on itch and pain by verbal suggestions | Q83480491 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | headache | Q86 |
| nocebo | Q1332954 | ||
| P304 | page(s) | 132-137 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Current Neurology and Neuroscience Reports | Q18206211 |
| P1476 | title | Nocebo in headaches: implications for clinical practice and trial design | |
| Nocebo in Headaches: Implications for Clinical Practice and Trial Design | |||
| P478 | volume | 12 |
| Q60910013 | Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis |
| Q90156744 | Learning mechanisms in nocebo hyperalgesia: the role of conditioning and extinction processes |
| Q37578354 | Learning to experience side effects after antidepressant intake - Results from a randomized, controlled, double-blind study |
| Q26778185 | New players in the preventive treatment of migraine |
| Q34311226 | Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta‐analysis |
| Q50616272 | Nocebo effects and psychotropic drug action |
| Q92510498 | Nocebo in Biosimilars and Generics in Neurology: A Systematic Review |
| Q38736906 | Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials |
| Q36108284 | Nocebo phenomena in medicine: their relevance in everyday clinical practice |
| Q58561333 | Nocebos in rheumatology: emerging concepts and their implications for clinical practice |
| Q58779477 | Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain |
| Q36786262 | Pain and suicidality: insights from reward and addiction neuroscience. |
| Q85366029 | Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation |
| Q34637199 | Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation |
| Q96306721 | The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice |
Search more.